186 related articles for article (PubMed ID: 28220555)
21. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
[TBL] [Abstract][Full Text] [Related]
22. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
23. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M; Marchesini E; Paladino E; Santoro C; Zanon E; Iorio A
Haemophilia; 2015 Mar; 21(2):204-209. PubMed ID: 25274155
[TBL] [Abstract][Full Text] [Related]
25. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction.
Baumann A; Piel I; Hucke F; Sandmann S; Hetzel T; Schwarz T
Eur J Pharm Sci; 2019 Mar; 130():11-20. PubMed ID: 30654111
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
29. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
31. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
[TBL] [Abstract][Full Text] [Related]
32. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
34. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
35. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
Suzuki A; Tomono Y; Korth-Bradley JM
Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
[TBL] [Abstract][Full Text] [Related]
37. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Solms A; Wang M
Eur J Haematol; 2020 Aug; 105(2):164-172. PubMed ID: 32259334
[TBL] [Abstract][Full Text] [Related]
38. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
39. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.
Garcia-Martínez I; Borràs N; Martorell M; Parra R; Altisent C; Ramírez L; Álvarez-Román MT; Nuñez R; Megias-Vericat JE; Corrales I; Alonso S; Vidal F
Thromb Haemost; 2020 Oct; 120(10):1395-1406. PubMed ID: 32726853
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay.
Lee CA; Owens D; Bray G; Giangrande P; Collins P; Hay C; Gomperts E; Schroth P; Barrowcliffe T
Thromb Haemost; 1999 Dec; 82(6):1644-7. PubMed ID: 10613649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
